Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Study Identifier:
ALXN1210-aHUS-311
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Jan 2017 - Jan 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Jan 2017 - Jan 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.
Trial Locations
Location
Status
Location
Clinical Trial Site
Fort Wayne, Indiana, United States, 46804
Status
N/A
Location
Clinical Trial Site
Fort Wayne, Indiana, United States, 46845
Status
N/A
Location
Clinical Trial Site
Durham, North Carolina, United States, 27705
Status
N/A
Location
Clinical Trial Site
Winston-Salem, North Carolina, United States, 27103
Status
N/A
Location
Clinical Trial Site
Columbus, Ohio, United States, 43210
Status
N/A
Location
Clinical Trial Site
Clayton, Australia
Status
N/A